Sandoz Group AG
A global leader in generic and biosimilar medicines.
SDZ | SW
Overview
Corporate Details
- ISIN(s):
- CH1243598427 (+2 more)
- LEI:
- 5493000JWK6XWFEUD320
- Country:
- Switzerland
- Address:
- Suurstoffi 14, 6343 Rotkreuz
- Website:
- https://www.sandoz.com/
- Sector:
- Manufacturing
Description
Sandoz Group AG is a global leader in generic and biosimilar medicines. The company's core activities involve the development, manufacturing, and distribution of off-patent pharmaceuticals to increase patient access to healthcare. Its business operates through two primary segments: Generics, which covers a wide range of small-molecule drugs, and Biosimilars, which are approved versions of original biologic medicines. Sandoz provides treatments for various diseases, including cancer and diabetes, and its product portfolio also includes key medicines such as antibiotics. The company's stated purpose is to pioneer access to medicines for patients worldwide.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2024-08-08 02:00 |
Sandoz reports second-quarter sales and half-year 2024 results
|
English | 53.6 KB | ||
| 2024-07-25 02:00 |
Sandoz launches biosimilar Pyzchiva® (ustekinumab) across Europe, to treat chro…
|
English | 7.3 KB | ||
| 2024-07-01 02:00 |
FDA approves biosimilar Pyzchiva® (ustekinumab-ttwe), to be commercialized by S…
|
English | 12.2 KB | ||
| 2024-05-22 02:00 |
Sandoz receives European Commission approval for Wyost® and Jubbonti®, the firs…
|
English | 9.5 KB | ||
| 2024-05-07 02:00 |
Sandoz reports first quarter 2024 sales
|
English | 28.7 KB | ||
| 2024-04-30 02:00 |
Shareholders approve all resolutions proposed by Board of Directors at Annual G…
|
English | 6.7 KB | ||
| 2024-04-22 02:00 |
Sandoz confirms European Commission approval of Pyzchiva® (ustekinumab), furthe…
|
English | 7.1 KB | ||
| 2024-03-21 01:00 |
Sandoz opens new antibiotic production facility in Austria, to significantly in…
|
English | 6.4 KB | ||
| 2024-03-13 01:00 |
Sandoz reports fourth quarter 2023 sales and full-year 2023 results
|
English | 88.2 KB | ||
| 2024-03-05 01:00 |
Sandoz receives FDA approval for first and only denosumab biosimilars
|
English | 21.2 KB | ||
| 2024-03-04 01:00 |
Sandoz acquires CIMERLI® business from Coherus, further building biosimilar and…
|
English | 9.8 KB | ||
| 2024-02-29 01:00 |
Sandoz US subsidiaries resolve generic drug antitrust class action litigation w…
|
English | 6.3 KB | ||
| 2024-02-01 01:00 |
Sandoz announces changes in the Board of Directors
|
English | 6.0 KB | ||
| 2024-01-31 01:00 |
Sandoz launches first and only biosimilar for multiple sclerosis, Tyruko® (nata…
|
English | 7.4 KB | ||
| 2024-01-22 01:00 |
Sandoz announces agreement to acquire CIMERLI® business from Coherus, strengthe…
|
English | 9.3 KB |
Automate Your Workflow. Get a real-time feed of all Sandoz Group AG filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Sandoz Group AG
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Sandoz Group AG via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-05-02 | N/A | Non-Executive member | Buy | None | 251,343.62 CHF |
| 2025-04-15 | N/A | Non-Executive member | Buy | None | 270,000.00 CHF |
| 2025-04-15 | N/A | Non-Executive member | Buy | None | 260,000.00 CHF |
| 2025-04-15 | N/A | Non-Executive member | Buy | None | 230,000.00 CHF |
| 2025-04-15 | N/A | Non-Executive member | Buy | None | 202,500.00 CHF |
| 2025-04-15 | N/A | Non-Executive member | Buy | None | 187,500.00 CHF |
| 2024-08-21 | N/A | Non-Executive member | Buy | None | 429,855.85 CHF |
| 2024-04-30 | N/A | Non-Executive member | Buy | None | 130,000.00 CHF |
| 2024-04-30 | N/A | Non-Executive member | Buy | None | 115,000.00 CHF |
| 2024-04-30 | N/A | Non-Executive member | Buy | None | 62,500.00 CHF |
Peer Companies
